US biotechnology company Novavax Inc (Nasdaq:NVAX) announced on Wednesday that the US Food and Drug Administration (FDA) has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19.
The formula was approved for adults aged 65 years and older, or individuals from 12 years with at least one underlying condition that puts them at high risk of severe outcomes from COVID-19.
Clinical and preclinical data have previously shown that Nuvaxovid is safe and effective for the prevention of COVID-19, and induces immunity across currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7 and XEC.
According to Novavax, Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the United States for the 2025-2026 vaccination season.
Novavax COVID-19 vaccine approved in US
Cantargia secures US patent for nadunolimab combination therapies
European Commission approves Bio-Thera Solutions' BAT2206
INOVIO to begin rolling submission of BLA for INO-3107
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Orsini named by Ionis as exclusive specialty pharmacy partner for DAWNZERA (donidalorsen)
Curasight's uTREAT clinical trial application approved in Europe
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Innovent Biologics receives approval over squamous cell lung cancer study
Crinetics Pharmaceuticals' atumelnant granted US FDA Orphan Drug Designation
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Hamlet BioPharma completes Phase II study of Alpha1H in non-muscle invasive bladder cancer